Genixcure Inc.
June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
153C
GENIXCURE develops next generation AAV capsids through its proprietary AI system, InsightMiner and it also develops AAV gene therapy programs to cure ALS, SMA, Alzheimer's disease and Lafora disease.
We pursue the full potential of AAV gene therapy by developing next generation capsids with enhanced tropism and transduction efficiency, clinical safety, and customized PD for them to ensure CMC compatibility of our capsids and programs.
In terms of business, the company focus on three areas derived from its AAV platform technology, as follows.
AAV capsid engineering for next generation AAV vectors
Non-GMP AAV production service (for research institutions, universities, and early-stage biotechs)
AAV-mediated therapeutic programs based on its proprietary AAV capsids
Company HQ City:
Suwon
Company HQ State:
Kyonggi-do
Company HQ Country:
Korea, Republic of
Year Founded:
2019
Lead Product in Development:
AI-powered AAV capsids and a therapeutic program for ALS based on one of the proprietary capsids
CEO
Mr.Hongsung Moon
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
Five of AAV capsids and two of therapeutic programs
When you expect your next catalyst update?
NHP treatment of capsid candidates from June, 2025 with a local CRO to marmosets
What is your next catalyst (value inflection) update?
end of this year, probably late November or early December this year
Website
www.genix-cure.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}